Navigation Links
ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
Date:9/23/2009

materially from any forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:

    ThromboGenics

    Dr. Steve Pakola, CMO                     Tel: +1(212)201-0920
                                              steve.pakola@thrombogenics.com

    Dr. Patrik De Haes, CEO                   Tel: +32-16-75-13-10
                                              patrik.dehaes@thrombogenics.com

    Citigate Dewe Rogerson

    Amber Bielecka/ David Dible/ Nina Enegren Tel: +44(0)207-638-95-71
                                              amber.bielecka@citigatedr.co.uk


'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2014)... , September 3, 2014 , ... expert re-joins the Company ~   ... Company"), a clinical stage biopharmaceutical company developing T-cell immunotherapy ... Dr. Jeroen Rovers , MD PhD, as its ... recently Chief Medical Officer at Ceronco Biosciences. Prior to ...
(Date:9/3/2014)... BUDAPEST, Hungary , Sept. 3, ... PTN; hereinafter: "Palatin") and Gedeon Richter Plc. (hereinafter: ... collaboration and license agreement to co-develop and commercialize ... the European Union, other European countries and additional ... company with a strong focus in female health ...
(Date:9/2/2014)... , Sept. 3, 2014  Edison Pharmaceuticals today ... placebo-controlled trial in pediatric patients. Rett syndrome patients ... in head circumference.  Decreased brain growth and head ... Rett syndrome is a genetic neurodevelopmental disorder ... 24 months of age. It is characterized by ...
Breaking Medicine Technology:Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 2Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 3Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 4Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 5Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 2Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 3Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 4Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter 5Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome 2Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome 3
... , the leading online Medical Transcription and Editing training ... NexGen Speech Recognition Editing and Medical Transcription Program. In ... MTEC is moving their curriculum to the next level. ... this important industry migration and is being provided to ...
... Medical Messenger , an innovative healthcare technology ... 4 is now certified to meet 2011-2012 criteria supporting ... and Reinvestment Act (ARRA) as a Complete EHR by ... record (EHR) software capable of enabling providers to meet ...
Cached Medicine Technology:MTEC Announces Release of NexGen Speech Recognition Editing and Medical Transcription Training Program 2Medical Messenger's AstralJet V4 Receives ONC-ATCB 2011/2012 Certification 2
(Date:9/3/2014)... 2014 CS3 Technology, a Sage North ... support of Sage 100 ERP, Sage 500 ERP, and ... Million Dollar Club achiever for surpassing a million dollars ... CS3 Technology and all Million Dollar Club achievers for ... Sage, its business partners and the mutual customers they ...
(Date:9/3/2014)... New Orleans, LA (PRWEB) September 03, 2014 ... 1st, at 201 ST. Charles, Suite 255B New Orleans, at ... this office. John was a litigation support manager at Baker ... Thompson & Knight LLP before joining LCI and has over ... for clients of all sizes. , LCI® began in the ...
(Date:9/3/2014)... 2014 Health information technology improves ... decreases medical errors, and strengthens the interaction between ... the important role health information technology plays in ... across the U.S. have joined together to celebrate ... 16-20, 2014. With the NHIT Week theme: One ...
(Date:9/3/2014)... Pwnie Express today announced the release of the ... R3, an inconspicuous pentesting device whose drop box form ... at a fraction of the cost of traditional penetration ... company to assess wired and wireless network security anywhere, ... penetration testing device in a portable, shippable, "Plug-and-Pwn" form ...
(Date:9/3/2014)... Immersion Active (ImmersionActive.com ), the digital agency for ... 2014 Content Marketing Awards presented by the Content Marketing ... program for people who create content for organizations. Categories ... , Immersion Active’s winning entry was the Alzheimer’s ... Senior Care®. This series addresses people who care for ...
Breaking Medicine News(10 mins):Health News:CS3 Technology Named a Sage Million Dollar Club Achiever for 2013-2014 2Health News:Grand Opening of Legal Concierge Inc.’s New Location 2Health News:Innovative Healthcare Solutions (IHS) Celebrates National Health IT Week September, 15-19, 2014 2Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 2Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 3Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 4Health News:Immersion Active Wins Silver for Email Strategy in 2014 Content Marketing Awards 2
... (Nasdaq: MEMY ) today announced the issuance ... matter patent,protection for a series of nicotinic alpha-7 ... which are both being developed,in partnership with Roche ... disease and cognitive impairment associated with schizophrenia,(CIAS). The ...
... Baby boomers are turning 62,every seven seconds. ... their,own health care in their senior years, says ... Care insurance lawyer., (Photo: http://www.newscom.com/cgi-bin/prnh/20070717/NYFNSC02 ), ... Care. It has been sold and,marketed to our ...
... ConvergeWireless Inc., of Ontario Canada, a Value Added Wireless Application ... been certified by the AT&T Developer Program. MyMileageGenie & MyFormsGenie ... for Enterprise Sales. , ... Ontario, ...
... DETROIT, Oct. 24 For the second ... has been chosen as the most,preferred hospital ... to the,2008 Cancer Treatment Preference Profile Survey ... http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITUTELOGO ), The annual survey, ...
... body, checking arteries lowers risk of further injury , , THURSDAY, ... is only the first step in saving a life after ... advisory, published in the Oct. 23 issue of Circulation ... resuscitation or risk the losing the patient to the original ...
... Alternext US: FIT), a leading provider of integrated,employee ... report financial results for the third quarter ended ... the market closes. The company will also,hold a ... results. Participating,in the call will be Dr. Gregg ...
Cached Medicine News:Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 2Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 3Health News:Expert Says Conseco Trust May Significantly Alter The Senior Health Care Market 2Health News:MyMileageGenie & MyFormsGenie Certified by the AT&T Developer Program 2Health News:MyMileageGenie & MyFormsGenie Certified by the AT&T Developer Program 3Health News:MyMileageGenie & MyFormsGenie Certified by the AT&T Developer Program 4Health News:Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan 2Health News:Speedy Care After Heart Attack Key to Survival 2Health News:HealthFitness Corporation to Report 2008 Third Quarter Financial Results 2
... Basic ergonomic chairs with ... with lumbar support • Select ... and casters and glides. • ... the following environments: industry, education, ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTT/1P chairs are recommended for ... clean room, static control, health care ...
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
Medicine Products: